XLO
Income statement / Annual
Last year (2024), Xilio Therapeutics, Inc.'s total revenue was $6.34 M,
and the percentage change from the previous year is not available.
In 2024, Xilio Therapeutics, Inc.'s net income was -$58.24 M.
See Xilio Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$6.34 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$1.90 M
|
$1.85 M
|
$1.50 M
|
$1.07 M
|
$240,000.00
|
| Gross Profit |
$6.34 M
|
-$1.90 M
|
-$1.85 M
|
-$1.50 M
|
-$1.07 M
|
-$240,000.00
|
| Gross Profit Ratio |
1
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$41.21 M
|
$52.14 M
|
$59.20 M
|
$51.19 M
|
$43.91 M
|
$14.26 M
|
| General & Administrative Expenses |
$24.78 M
|
$27.00 M
|
$29.95 M
|
$23.86 M
|
$10.65 M
|
$4.77 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$24.78 M
|
$27.00 M
|
$29.95 M
|
$23.86 M
|
$10.65 M
|
$4.77 M
|
| Other Expenses |
$937,000.00
|
$0.00
|
$927,000.00
|
-$756,000.00
|
-$656,000.00
|
$1.72 M
|
| Operating Expenses |
$66.93 M
|
$79.13 M
|
$89.15 M
|
$75.04 M
|
$54.56 M
|
$19.03 M
|
| Cost And Expenses |
$66.93 M
|
$79.13 M
|
$89.15 M
|
$75.04 M
|
$54.56 M
|
$19.03 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$600.00
|
$600.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$600,000.00
|
$600,000.00
|
$0.00
|
| Depreciation & Amortization |
$1.64 M
|
$1.90 M
|
$1.85 M
|
$1.50 M
|
$1.07 M
|
$240,000.00
|
| EBITDA |
-$58.00 M |
-$73.80 M |
-$85.58 M |
-$73.70 M |
-$53.50 M |
-$17.07 M |
| EBITDA Ratio |
-9.14
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-9.55
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$2.34 M
|
$2.73 M
|
$927,000.00
|
-$756,000.00
|
-$656,000.00
|
$1.72 M
|
| Income Before Tax |
-$58.24 M
|
-$76.40 M
|
-$88.22 M
|
-$75.80 M
|
-$55.22 M
|
-$17.31 M
|
| Income Before Tax Ratio |
-9.18
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$927,000.00
|
-$1.50 M
|
$858,703.00
|
$68,140.00
|
| Net Income |
-$58.24 M
|
-$76.40 M
|
-$87.30 M
|
-$74.30 M
|
-$55.22 M
|
-$17.31 M
|
| Net Income Ratio |
-9.18
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.09 |
-2.78 |
-3.19 |
-2.72 |
-2.01 |
-0.0006 |
| EPS Diluted |
-1.09 |
-2.78 |
-3.19 |
-2.72 |
-2.01 |
-0.0006 |
| Weighted Average Shares Out |
$53.51 M
|
$27.50 M
|
$27.39 M
|
$27.36 M
|
$27.47 M
|
$27.47 B
|
| Weighted Average Shares Out Diluted |
$53.51 M
|
$27.50 M
|
$27.39 M
|
$27.36 M
|
$27.47 M
|
$27.47 B
|
| Link |
|
|
|
|
|
|
